Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Donna Carstens_2024
VIEWPOINTS

SEA Management: Donna Carstens from AstraZeneca in a Riveting Conversation with PharmaShots

Shots:  Recently AstraZeneca’s FASENRA (benralizumab) received approval from the US FDA as an add-on maintenance treatment for patients (≥ 6 yrs.) with severe asthma and with an eosinophilic phenotype  Today, at PharmaShots we have with us Donna Carstens, Senior Medical Director Respiratory, Fasenra at AstraZeneca  Donna shares insights from the TATE study an open-label, multinational,…
June 3, 2024

Read more

Astrazeneca
NEWS

AstraZeneca’s Tagrisso Receives the CHMP’s Positive Opinion for Treating EGFR-Mutated advanced Lung Cancer 

      Shots:  The CHMP’s positive opinion of Tagrisso + pemetrexed & Pt-based CT as a 1L treatment of locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC with exon 19 deletions or exon 21 (L858R) mutations was based on P-III (FLAURA2) study  The P-III (FLAURA2) study assessed Tagrisso (80mg, oral, QD) + CT [pemetrexed…
June 3, 2024

Read more

VIEWPOINTS_Andrew Menzies-Gow1_Michael Wechsler2_2024
VIEWPOINTS

EGPA Remission with Fasenra: Michael Wechsler and Andrew Menzies Gow in Conversation with PharmaShots

Shots:  An already established biologic treatment for SEA in the US, EU5 & Japan. Fasenra is now showing exemplary remission for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA)  Today, at PharmaShots, we have a distinguished panel of speakers shedding light on advancements under the P-III MANDARA study and the recent publication of the study…
May 15, 2024

Read more

Astrazeneca
NEWS

AstraZeneca’s Truqap Plus Faslodex Receives the CHMP’s Positive Opinion for Treating Breast Cancer 

Shots:  The CHMP's positive opinion was based on the P-III (CAPItello-291) study assessing Truqap + Faslodex vs PBO + Faslodex to treat ER+, HER2‑ locally advanced or metastatic breast cancer patients (n=708) having ≥1 PIK3CA, AKT1 or PTEN-alterations after recurrence or progression on or after an endocrine-based regimen  The study demonstrated reduction in the disease…
April 29, 2024

Read more

RNAi Therapeutic Top 20 2024
TOP 20

Top 20 RNAi Therapeutic Companies of 2024

Shots:  RNAi therapeutics are innovative medications that enable rapid identification of specific inhibitors of disease targets across a wide range of molecule classes. Several biopharma companies are investing in RNAi therapeutics extravagantly to maintain a healthy foothold in innovative medicines  In 2023, the global RNAi drug delivery market size was valued at $84.1B and is…
April 25, 2024

Read more

VIEWPOINTS_David Jackson_2024
VIEWPOINTS

SEA Management with Fasenra: David Jackson & Fasenra Team (AZ) Share Insights from the SHAMAL P-IV Study

Shots:  David Jackson and AstraZeneca’s Fasenra Team, in an engaging conversation with PharmaShots highlight the key findings from the SHAMAL P-IV study  SHAMAL is the first-ever prospective study that investigated the potential of targeted biologic treatment to enable a significant step down of inhaled corticosteroid (ICS) therapy in severe asthma patients  SHAMAL showcased that ICS…
March 20, 2024

Read more

Astrazeneca
NEWS

AstraZeneca’s Voydeya Receives CHMP’s Recommendation for Treating Paroxysmal Nocturnal Haemoglobinuria (PNH) with Residual Haemolytic Anaemia

Shots:   The CHMP has recommended Voydeya as an add-on therapy to SoC for treating PNH adult patients with residual haemolytic anaemia  The recommendation was based on the P-III (ALPHA) study investigating the safety & efficacy of Voydeya as an add-on therapy to Ultomiris or Soliris (SoC) for treating PNH patients with extravascular haemolysis (EVH)  The…
February 26, 2024

Read more

Load more